Corrigendum: Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma

Domenica Lorusso; Romano Danesi; Laura Deborah Locati; Gianluca Masi; Ugo De Giorgi; Angiolo Gadducci; Sandro Pignata; Roberto Sabbatini; Antonella Savarese; Giorgio Valabrega; Claudio Zamagni; Nicoletta Colombo

doi:10.3389/fonc.2023.1232476

Corrigendum: Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma

Front Oncol. 2023 Aug 7:13:1232476. doi: 10.3389/fonc.2023.1232476. eCollection 2023.

Authors

Domenica Lorusso^{1

2}, Romano Danesi³, Laura Deborah Locati^{4

5}, Gianluca Masi^{6

7}, Ugo De Giorgi⁸, Angiolo Gadducci⁹, Sandro Pignata¹⁰, Roberto Sabbatini¹⁰, Antonella Savarese¹¹, Giorgio Valabrega¹², Claudio Zamagni¹³, Nicoletta Colombo^{14

15}

Affiliations

¹ Department of Clinical Research Planning, Fondazione Policlinico Universitario A Gemelli Istituto di Ricerca e Cura a carattere scientifico (IRCCS), Rome, Italy.
² Department of Life Science and Public Health, Catholic University of Sacred Heart, Rome, Italy.
³ Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
⁴ Translational Oncology Unit, Istituto di Ricerca e Cura a carattere scientifico (IRCCS) Istituti Clinici Scientifici (ICS) Maugeri, Pavia, Italy.
⁵ Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy.
⁶ Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
⁷ Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
⁸ Department of Medical Oncology, Istituto di Ricerca e Cura a carattere scientifico (IRCCS) Istituto Romagnolo per lo Studio dei Tumori (IRST), Dino Amadori, Meldola, Italy.
⁹ Department of Clinical and Experimental Medicine, Division of Gynecology and Obstetrics, University of Pisa, Pisa, Italy.
¹⁰ Department of Urology and Gynecology, Istituto Nazionale Tumori Istituto di Ricerca e Cura a carattere scientifico (IRCCS) "Fondazione Giovanni Pascale", Naples, Italy.
¹¹ Division of Medical Oncology 1, Istituto di Ricerca e Cura a carattere scientifico (IRCCS) -Regina Elena National Cancer Institute, Rome, Italy.
¹² University of Torino-Struttura Complessa a Direzione Universitaria (S.C.D.U.) Oncologia Azienda Ospedaliera (A.O) Ordine Mauriziano-Ospedale Umberto I, Torino, Italy.
¹³ Addarii Medical Oncology, Istituto di Ricerca e Cura a carattere scientifico (IRCCS) Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
¹⁴ School of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy.
¹⁵ Department of Oncological Gynecology, European Institute of Oncology (IEO) Istituto di Ricerca e Cura a carattere scientifico (IRCCS), Milan, Italy.

Abstract

[This corrects the article DOI: 10.3389/fonc.2022.979519.].

Keywords: endometrial cancer; immune response; lenvatinib; pembrolizumab; tyrosine kinase inhibitor.

Publication types

Published Erratum